35 research outputs found
Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network
Objectives In lupus nephritis the pathological diagnosis from tissue retrieved during kidney biopsy drives treatment and management. Despite recent approval of new drugs, complete remission rates remain well under aspirational levels, necessitating identification of new therapeutic targets by greater dissection of the pathways to tissue inflammation and injury. This study assessed the safety of kidney biopsies in patients with SLE enrolled in the Accelerating Medicines Partnership, a consortium formed to molecularly deconstruct nephritis.Methods 475 patients with SLE across 15 clinical sites in the USA consented to obtain tissue for research purposes during a clinically indicated kidney biopsy. Adverse events (AEs) were documented for 30 days following the procedure and were determined to be related or unrelated by all site investigators. Serious AEs were defined according to the National Institutes of Health reporting guidelines.Results 34 patients (7.2%) experienced a procedure-related AE: 30 with haematoma, 2 with jets, 1 with pain and 1 with an arteriovenous fistula. Eighteen (3.8%) experienced a serious AE requiring hospitalisation; four patients (0.8%) required a blood transfusion related to the kidney biopsy. At one site where the number of cores retrieved during the biopsy was recorded, the mean was 3.4 for those who experienced a related AE (n=9) and 3.07 for those who did not experience any AE (n=140). All related AEs resolved.Conclusions Procurement of research tissue should be considered feasible, accompanied by a complication risk likely no greater than that incurred for standard clinical purposes. In the quest for targeted treatments personalised based on molecular findings, enhanced diagnostics beyond histology will likely be required
Structural Coupling of Smad and Runx2 for Execution of the BMP2 Osteogenic Signal*
Two regulatory pathways, bone morphogenetic protein (BMP)/transforming
growth factor-β (TGFβ) and the transcription factor RUNX2, are
required for bone formation in vivo. Here we show the interdependent
requirement of these pathways to induce an osteogenic program. A panel of
Runx2 deletion and point mutants was used to examine RUNX2-SMAD
protein-protein interaction and the biological consequences on BMP2-induced
osteogenic signaling determined in Runx2 null cells. These cells do
not respond to BMP2 signal in the absence of Runx2. We established
that a triple mutation in the C-terminal domain of RUNX2, HTY (426-428),
disrupts the RUNX2-SMAD interaction, is deficient in its ability to integrate
the BMP2/TGFβ signal on promoter reporter assays, and is only marginally
functional in promoting early stages of osteoblast differentiation.
Furthermore, the HTY mutation overlaps the unique nuclear matrix targeting
signal of Runx factors and exhibits reduced subnuclear targeting. Thus,
formation of a RUNX2-SMAD osteogenic complex and subnuclear targeting are
structurally and functionally inseparable. Our results establish the critical
residues of RUNX2 for execution and completion of BMP2 signaling for
osteoblastogenesis through a mechanism that requires RUNX2-SMAD
transcriptional activity